Human immunoglobulin M (IgM) rheumatoid factors (RFs) show primary direct enzyme-linked immunosorbent assay (ELISA) reactivity with Fab rather than Fc fragments of monoclonal antibody (mAb) II-481 directed against the Fc3'-binding site of herpes simplex virus glycoprotein gE. This preferential anti-Fab specificity suggests that RFs react with antigen-binding portions of mAb II-481 as anti-idiotypic antibodies directed at the combining site regions of mAb reacting with the Fc3'-binding region of gE. Analysis of this idiotype-anti-idiotype reaction employed polymerase chain reaction amplification and sequencing of the variable heavy and light (VH and VL) regions of mAb 11-481. When VH and VL regions of mAb II-481 were synthesized as overlapping 7-met peptides on polypropylene pins, a panel of 10 polyclonal and 6 rnonoclonal human IgM RFs reacted primarily with epitopes within the three solvent-exposed mAb 11-481 complementarity determining regions (CDRs). Preincubation of single CDR heptamer peptides with IgM RFs in free solution, resulted in 63-100% inhibition of RF binding to mAb II-481 on the ELISA plate, confirming the antigenic importance of linear CDR regions for RF reactivity. Combinations of two or three CDR peptides frequently produced 94-100% inhibition of RF binding to whole mAb II-481. Control peptides, singly or in combination, showed no inhibition. Computer modeling suggested that the R.F-reactive mAb II-481 Fv region and a previously demonstrated R.F-reactive CH3 epitope displayed considerable three-dimensional similarities in conformation. These studies may provide insight into limited shape homologies possibly involved in an R.F anti-idiotypic reaction.
H
uman RFs represent one of the first types of autoantibodies ever described (1, 2) , and over the five decades since their initial description, have provided a fascinating subject to study in parallel with the humoral immune response in rheumatoid arthritis (RA): (3) (4) (5) (6) (7) . The original observations on immunochemical and serologic reactions of RFs indicated that they represented autoantibodies directed at sites on the Fc region of human IgG. Indeed the primary anti-Fc specificity of human RFs was supported by formation of 22S and 11S complexes when 19S IgM or 7S IgG RFs reacted with autologous IgG (3) (4) (5) . Moreover, anti-Fc specificity of human RFs was also supported by a multitude of studies of antiallotypic RF specificity for Gm determinants dependent 1 Abbreviations used in thispaper: FR1, framework region 1; gE, glycoprotein E; R.A, rheumatoid arthritis. on localized single or double amino acid substitutions within various regions of CH3 and CH2 of the Fc portion of IgG (8) (9) (10) .
Recently, there have been a number of indications that, besides Fc, human RFs may have other parallel specificities such as the Pab portion of monoclonal mouse IgG antibodies directed at the Fc'y-binding region of the HSV glycoprotein E (gE) (11, 12) . The reaction of human IgM RFs from patients with RA with the mouse monoclonal IgG-2b antibody II-481 to gE (the HSV-1 Fcy-binding protein) was shown to resemble an idiotype-anti-idiotype reaction since, in most instances, RFs reacted much more strongly with Fab than with Fc fragments of mAb II-481 (12) . If R.Fs from patients with RA react as anti-idiotypes against the Fv regions of mAb I1-481 directed at the Fcy-binding regions of gE, then the Fab portion and presumably the three CDRs of mAb II-481 should contain immunodominant antigenic epitopes very similar or identical to RF-reactive regions on the Fc portion of IgG (13, 14) . The present report provides evidence which supports that this is indeed the case. Moreover, data presented here also provide molecular and single amino acid epitope definition of an idiotype-anti-idiotype reaction between a common human autoantibody (R,F) and the Fv portion of mAb II-481 directed at the Fc3/-binding region of the herpes simplex gE (14) . The results presented here also suggest that similar conformations may be shared between the RF-reactive Fv regions of mAb II-481 and RF-reactive sites on CH3 of IgG.
Materials and Methods
Mouse Monoclonal Cell Lin~ The cell line II-481 B-2.4 producing the IgG-2b mouse mAb 11-481 (15) directed at gE of HSV-1 was kindly provided by Dr. Pat Spear (Northwestern University Medical School, Chicago, IL) and was grown in OPTI-MEM media (GIBCO BRL, Gaithersburg, MD) supplemented with 5% FCS, 0.3 mg glutamine, 100 U of penicillin, and 0.1 mg streptomycin (Sigma Chemical Co., St. Louis, MO) per ml. Cells were collected by centrifugation and supernatants tested for reactivity with isolated gE (5 ~g/ml) as well as with whole HSV-1 by ELISA (11, 12) . The cell line mAb product 11-481 showed strong anti-gE specificity.
mRNA Isolation and cDNA Synthesis. mRNA was isolated from 3 x 10 s cells using the Fast Track mRNA Isolation Kit (Invitrogen, San Diego, CA). Briefly, cells were lysed in detergentbased buffer containing RNase and protein degrader and applied to oligo (dT) cellulose for adsorption. DNA, dissolved membranes, proteins, cell debris, and nonpolyadenylated RNAs were washed off the resin with salt buffers while the mRNA was eluted in the absence of salt. Purity and concentration of the mRNA was determined spectrophotometrically. Transcription of mRNA into first strand cDNA was performed according to the method of Gubler and Hoffman (16) with the cDNA Synthesis Kit from Boehringer Mannheim Biochemical (Chicago, IL). Briefly, the mRNA sample was heated to 65~ for 5 min and then incubated with AMV reverse transcriptase, oligo (dT) 15 primer or random primer, p(dN)6, RNase inhibitor, and deoxynucleotide mixture at 42~ for 1 h.
Oligonucleotide Primers. The oligonucleotide primers used in PCR are shown in Fig. 1 . The 5' primer for the light and 3' primers for the L and H chains were those of Larrick and co-workers (17, 18) whereas the 5' primer for the H chain was from Orlandi et al. (19) . Originally, the primers were designed from known sequences of mouse IgG antibodies (20, 21) . The 5' primers were constructed from information available on conserved sequences of the first framework regions (FR1) of L and H chains, whereas the 3' primers were designed for annealing within the constant regions of C K L chains or CH 1 H chains. EcoRI and HindlII restriction sites were added to the 5' and 3' primers, respectively. Two bases (G) were added outside the restriction endonuclease site to improve enzyme digestion.
PCR. 2/~1 of the cDNA-RNA hybrid and 100 pmol of the primer were added to the PCR mixture (GeneAmp; Perkin Elmer Cetus, Norwalk, CT) in a total volume of 100/~1. Amplification was done in a thermal cycler for 40 cycles (Perkin Elmer Cetus). Each cycle consisted of heating to 94~ for 1 min, primer annealing at 55~ for 3 rain, and primer extension at 72~ for 3 min. PCR products were analyzed with ethidium bromide on a 2% agarose gel.
Cloning and DNA Sequencing. PCR bands were reamplified be- . The amino acid residues making up positions 20-105 on the VH and 14-100 on the VL regions of mAb II-481 were synthesized as overlapping 7 mers on Geysen pins as previously described (14, (22) (23) (24) (25) (26) (27) . Pins containing the VH or VL primary amino acid sequences were then tested directly with a panel of 10 a~nity-isolated polyclonal and 6 monoclonal human IgM RFs obtained as previously described (22) (23) (24) . The procedure for testing of the pins containing the overlapping 7 mers of VH or VL followed the procedure previously outlined in detail (14) . Synthesis control pins containing the peptides with the sequences PLAC and GLAC were incubated with the positive control mAb (PT-02-20027; Cambridge Research Chemicals, Cambridge, MA). The next day, the pins were washed four times for 10 rain with PBS containing 0.05% Tween-20. Depending on the primary reacting antibody, the pins were then incubated with peroxidaseconjugated goat F(ab')2 anti-human IgM (for human IgM RF) or anti-mouse IgG (Jackson Laboratories, West Grove, PA) diluted in PBS containing 1% BSA, 200 #g/well, for 1.5 h at room temperature. After four wash steps, the pins were incubated with the O-phenylene-diamine substrate and color developed for 15 min. After completions of assays, a disruption procedure was employed to remove bound antibodies as previously described (14, 23, 24) . Pins could then be reused 25-35 times before losing their antigenicity. . After distinct RF-reactive linear sequences had been identified within the VL or VH CDRs using the pin ELISA assay, these reactive regions were synthesized as eight free heptamer peptides using the original Merrifield technique (28). These CDR peptides were used in competition/inhibition ELISA assays with RFs reacting with mAb 11-481 on the ELISA plate. Titrations of increasing amounts of RF reacting with mAb II-481 (5 #g/ml) on the plate were used to establish the maximum binding concentration of each RF. Concentrations of RF producing 50% maximum binding were preincubated with a broad micromolar range of each of the eight CDR peptides before completion of the ELISA reaction between the RF and mAb II-481 on the plate. In many instances, various combinations of VL or VH mAb II-481 CDR peptides were studied to determine if inhibition of RF binding was increased using several peptides derived from different CDR regions. Several control peptides were used in parallel. A laminin peptide of the same length but no homologous sequence (CIKVSVS) was used as one control. Additional control peptides included: GMERVRWCATDGEG (melanoma peptide); LHNHYT (peptide from Cv3 of human IgG); CNSRQTDREDELI (Klebsiella peptide); ADAQTDREDLRTLLRY (HLA B27 peptide); AAE-DWCKKGDT (IgA Cy3 peptide); and NSRQTDR (KlebsieUa peptide). Positive control inhibition was obtained with whole mAb 11-481 or Fc of IgG.
Synthesis of CDR Peptides and Inhibition of RF Binding to mAb
Computer Analysis ofli-481 Sequences. We used the previously established three-dimensional structure of the Fab portion of mouse IgG mAb D1.3 (29) available through the Brookhaven Data Base to provide a template for a tentative model of the VH and VL pot-tions of mAb I1-481. Since the first eight amino acid residues of the VH and VL chains of mAb 11-481 were missing because of primer annealing, these residues were replaced by the first eight amino acids from the VH chain of mAb Id B5.7 (30) , and the missing residues for the VL chain by those from mAb A17 (31) . In the comparable FRs of these latter mAbs, the amino acid residue homologies were 89% identical for the VH and 94% identical for VL to those of mAb 11-481. Therefore, it was assumed that a similar homology existed for the first eight amino acids in the rather conserved FILl regions of mAbs Id B5.7, A17, and II-481.
The sequences of the Fab portions of mouse mAb D1.3 and human mAb 11-481 were aligned using the BESTFIT sub-routine of the GCG package (version 7.0; Genetics Computer Group, Madison, WI) (32) . The overall identity was 80% for the L chain and 81% for the H chain and thus justified the use of standard methods of modeling by homology. The program used was Sybyl version 6.0 (Tripos Associates, Inc., St. Louis, MO) running on the VAX 4000-60 workstation. Structures were displayed on the Evans and Sutherland PS390 graphics system.
The loops of the H chain were modeled using the LOOP subroutine from Sybyl and the backbones displaying the smallest random mean square deviation values were selected. Individual amino acid substitutions were made using the MUTATE command in the BIOPOLYMER module. After the whole H chain was built, the structure was optimized for side-chain geometry and energy minimized employing the MAXIMIN2 module (1,000 cycles, no electrostatics, and vacuum conditions) with a standard Tripos force field.
To model the L chain of the Fab portion of IgG mAb II-481, the H chain ofmAb D1.3 was replaced with the above constructed H chain of mAb II-481 and the resulting hybrid was used in the subsequent modeling. An attempt to model both chains separately did not provide satisfactory results. Therefore, the loops containing residues 26-32 and 90-96 of the L chain were modeled in the hybrid as described for the H chain. The whole structure was optimized for the side chain geometry and energy minimized as described above for the H chain modeling. In particular, the linear amino acid sequences within the three solvent-accessible CDR regions of the VL and VH of mAb II-481, which showed direct reactivity with tLFs in pin ELISA, could be visualized and their physical proximity estimated. This strategy also allowed for construction of a tentative shape of the mAb II-481 combining site using space-fiUing spheres based on Connolly solvent-accessible surfaces (33) . The whole modeling procedure was verified by using VL and VH sequences of other IgG 2bK mouse mAbs such as IL19.9 (34, 35) which had already been extensively studied with respect to three-dimensional crystal structures. The validation process confirmed that the modeling steps we used accurately predicted most elements of Fv structure of previously studied mouse IgG 2bK antibodies where the crystal structures had been established. However, these predictions, of course, were not always perfect since the hypervariable regions of some antibodies actually assumed only one of several possible conformations.
Results
mRNA from the hybridoma cell line producing mAb II-481 was isolated and transformed by reverse transcriptase to cDNA-RNA hybrids. When the DNA sequence of the VL and VH regions of the Fv portion of mAb II-481 was amplified by PCR from the cDNA-RNA hybrids, the L chain primer pair (5'-EcoRI/FR1-ML [K] and 3'-HindlII/ML [K] constant) gave a major PCtL product of *400 bp whereas the H chain (Fig. 2) .
After the PCR products were ligated into plasmid pGem 3Zf(+), they were cloned and sequenced. The nucleotide and amino acid sequences of the L and H chain variable regions including the four FR and three C D R regions are shown in Fig. 3 , A and B. The variable L and H chain regions consisted of 107 and 113 amino acid residues, respectively. The L chain was identified as mouse K subgroup I and the H chain as subgroup IB (21) . mRNA of two independent clones from the mAb II-481-producing cell line was isolated and from each PCRamplified mRNA-cDNA hybrid, two clones were selected and completely sequenced. In all, four separate sequences from the VL and four from the VH were obtained. No mutations were detected in the four sequenced clones from L chain. In one of the four clones from the H chain, G was substituted for C at amino acid 77, changing the corresponding amino acid residue Gln to His at this position. 
iiiiiiiiii IIIIIIIIIIIIIIIIIllllllllllllllllllllllllllllllllllllllllllll reactivity with mAb 11-481 VL 7 mers are shown in Table  2 . Five ILFs reacted with epitopes from all three CDR regions, two reacted with two CDRs, and three with only one CDR. Of interest was the epitope represented by SGVPDRF which occurred largely just after the second CDP, in the FR3 region. This region contained only one residue (the serine at position 56) within the CDR-2. For monoclonal IgM RFs, the profile of VH reactivity is shown in Table 3 . Four of the six monoclonal RFs reacted with 7 mers which included one or more residues from all three CDRs. One monoclonal RF reacted with two CDRs and one (H4) with only one CDR. The VL reactivity profile for three monodonal IgM RF is shown in Table 4 . Two of three showed reactions with residues within all three CDRe; the third (H4) showed a strong reaction with only one CDP,.
Cross-inhibition of lgM RF Reacting with mAb 11-481 Using mAb 11-481 CDR Peptides, A series of inhibition experiments
was conducted in which polyclonal IgM RFs known to react with the Fab portion of mAb II-481 were preincubated with peptides synthesized from the CDR RF-reactive regions of mAb II-481 before completion of the ELISA reaction between RFs and mAb II-481 on the ELISA plate.
Results of competition ELISA assays using peptides from the three CDRs of mAb II-481 to inhibit the binding of various polyclonal IgM RFs to I1-481 on the ELISA plate are shown in Table 5 and Fig. 6 . It can be seen that the patterns of CDR peptide inhibition were quite different for each RF tested and that within the profile of peptides tested, at least one CDR 7-mer peptide showed maximum inhibition for each RF (63-100%). Results of these inhibition experiments correlated quite well with the pin ELISA direct binding assays where the entire I1-481 VH or VL linear sequence had been previously assayed. Of interest was the major degree of inhibition (62-90%) recorded with the SGVPDRF peptide from the CDP,-1 VL region and the high levels of inhibition (80-100%) found with CDR-2 VH peptide HIWWNDN when individual polyclonal IgM RFs were tested. Fig. 6 shows final 96% inhibition for CDR-2 VH peptide HIWWNDN with P,F AGEB. and a broad range of lesser inhibition with the other CDR peptides tested. No inhibition was recorded for the control laminin 7-met peptide CIKVAVS or the five other control peptides, and complete inhibition was always recorded when either whole Fc fragment or mAb 11-481 was used as inhibitor. When mAb II-481 CDR peptides were used as inhibitors of RFs binding to whole II-481 on the ELISA plate, a broad range of micromolar concentrations of peptides were tested and maximum inhibition of RF binding was found with highest peptide concentrations tested. By contrast, much lower concentrations of whole Fc or whole mAb II-481 were sufficient for complete inhibition (Fig. 6) .
It can be seen from Table 5 that with all RFs tested for inhibition using single CDR peptides, usually one or two such peptides showed highest levels of inhibition varying from 28-100%. In no instance did any of the panel of six control peptides show inhibition. Accordingly, a second kind of inhibition experiment was conducted in which combinations of two or three I1-481 CDR peptides were tested for inhibition of RF binding to mAb II-481 on the ELISA plate. Typical results are shown in Table 6 . It can be seen that combinations of two or three CDR peptides almost always showed an increment of inhibition beyond what had been recorded with the single CDR peptides alone. In some instances, the percent inhibition was actually higher than the sum of inhibitions with the single peptides tested alone as inhibitors, and in only two instances (RF LOP and ABR), the two inhibiting peptides studied together did not far surpass the degree of inhibition recorded when the CDR. peptides were tested alone. From Table 6 it can also be seen that combinations of two or three CDR peptides produced 50-100% inhibition with 88-100% inhibition in 10 of 12 experiments. The fact that two or sometimes three CDR peptides produced an increment in observed inhibition of RF binding over what had been recorded with single CDR peptides provided additional confirmation of the validity of the assays. 
Computer Modeling and Analysis of mAb 11-481 RF-reactive Regions.
A three-dimensional representation of the mAb II-481 was constructed using the previously established structures of mouse mAb D1.3 (29), B5.7 (30) , and mAb A17 (31) as described in Materials and Methods. It was quite clear that major differences in conformation appeared within the Fv regions of the respective molecules (Fig. 7, A and B) . The solvent-accessible, RF-reactive CDR regions of mAb 11-481 were then highlighted on our model and are shown in Fig.  7 C with blue highlighting the H chain RF-reactive CDRs and yellow, the L chain RF-reactive CDK regions. An estimate of the actual shape of the mAb I1-481 combining site was generated using Connolly solvent-accessible surfaces (33) . This showed that the Fv region of mAb II-481 exhibited a characteristic Mexican hat (sombrero) appearance (Fig. 8 A) . Because this shape very much resembled a prominent RFreactive epitope on CH3 previously studied in some detail (36) (Fig. 8 B) , direct comparisons of the topographical similarities of these two RF-reactive regions-the hypothetical too- Table 5 ). * Numbers indicate percent maximum inhibition with indicated combinations of CDR peptides tested over a broad micromolar concentration range. s Control peptides tested with RFs included CIKVAVS (laminin); GMERVRWCATDGEG (melanoma); LHNHYT (human Cv3); CNSRQTDREDELI (KlebsieUa); ADAQTDREDLRTLLRY (HLA B27); AAEDWCKKGDT (IgA Cs3); and NSRQTDR (Klebsiella). None singly or in combination showed any inhibition of RF binding to mAb 11-481.
deled structure of the Fv portion of mAb II-481 and the previously identified CH3 region-were made using the Sybyl computer graphics program. The remarkable apparent similarities in shape between these two different RF-reactive regions of entirely different antibody molecules are illustrated in Fig.  8 C. When 10 A sections of the Fv RF-reactive region of mAb II-481 were examined (Fig. 8, D and E) , preservation of the Mexican hat sombrero configuration was noted at many different levels. These comparisons supported a marked hypothetical conformational similarity between the two completely different RF-reactive Ig domains: the Fv portion of mAb 11-481 and the CH3 region of human IgG.
Discussion
HSV induces Fcy-binding proteins on infected cells and on virions. These Fc'y-binding proteins are coded for by the HSV genome and are able to bind the Fc part of human IgG (37-39). Mouse mAb II-481 reacts with the HSV-1 Fc'ybinding protein, gE, and the binding site of the mAb is directed at the Fc binding site on gE (14) .
In the present study we have examined the reactions of human polyclonal and monoclonal IgM RFs with mouse mAb II-481 directed at the Fc3,-binding glycoprotein of HSV-1 as an example of an idiotype-anti-idiotype reaction. The opportunity to study this reaction was provided by our previous observations that many human RFs reacted with the Fab antigen-binding portions of mAbs to herpesvirus Fcy-binding glycoproteins (12, 14) . These findings suggested that some KFs could be generated as anti-idiotypic antibodies directed against HSV-1 Fey-binding proteins (11, 12, 13, 40) as shown in Fig. 9 . The reaction between mAb I1-481 and R.F was inhibited by either IgG or highly purified gE (the Fcy-binding herpes glycoprotein) (11, 12) . Moreover, using an entirely different mAb (88-S) also directed against the Fc3/-binding protein of HSV-2, a similar ILF specificity was demonstrated. Positive reactions were recorded for KF reacting with whole mAbs II-481 and 88-S and with their Fab but not their Fc fragments (12) . These findings indicated that combining sites of many KFs may react with Fv regions of antibodies reacting with Fc3~-binding regions of the two herpesviruses HSV-1 and HSV-2.
If RFs from patients with RA react as anti-idiotypes against the Fv regions ofmAb II-481, the antibody combining regions, therefore, the six (three VH, three VL) CDKs of mAb II-481 should contain antigenic epitopes very similar or identical to antigenic regions on CH3 and CH2 of human IgG reacting with human KF. Evidence supporting this latter hypothesis has been presented in the present report. The primary amino acid sequence of the VH and VL regions ofmAb 11-481 was established by PCK mKNA expansion and sequencing of the eDNA from the cell line producing the mAb. When the primary amino acid sequences of VH and VL mAb I1-481 had been established, the entire solvent-accessible VH and VL regions of the latter were synthesized and tested as overlapping heptamers for RF reactivity. This approach showed Finally, the three-dimensional shape or conformation of the Fv portion of mAb 11-481 was modeled using computer graphics and coordinates established for several template mAbs previously studied. It must be emphasized that our threedimensional model of mAb 11-481 is still theoretical and will require confirmation when gE and Fab II-481 have been crystallized and studied for their exact three-dimensional structure. However, when the spacial distribution and shape of the Fv portion of mAb II-481 was estimated using approximation of the areas of the individual atoms involved, a sombrero conformation was found. This particular shape bore a striking resemblance to a previously identified CH3 epitope showing strong RF reactivity (36) . This latter epitope was based on established three-dimensional CH3 structure according to Diesenhoffer et al. (41, 42) . Of interest was the fact that the CH3 epitope visualized in its three-dimensional conformation showed such a striking homology of shape with the theoretical model of the Fv region of mAb II-481 constructed using our modeling procedure. This region contained the two histidines at positions 433 and 435 and the tyrosine at 436, which had previously been identified as important epitopes for RF reactivity (43) . Although an exact homologous sequence to the EGLHNHY at this region (residues 430-436 in CH3) was not present in the Fv region of mAb II-481, it was clear that the two regions shared many similarities in conformation. Thus a number of separate lines of evidence presented in the present report provide intimate insight into precise residues within the Fv ofmAb II-481 idiotype reacting with RFs in an idiotype-anti-Id reaction. The primary reactivity of the polyclonal and monoclonal RF with the CDR-1, -2, and -3 regions confirmed that such RFs react with regions contributing to the antigen binding sites of mAb II-481 directed against the Fcy-binding protein of HSV-1. Data presented here also provide a detailed structural basis for the idiotypic-anti-idiotypic reactivity of human KFs with the Fab fragment of mAb II-481.
Additional support for a structural resemblance between some KFs and the HSV-Fcy-binding protein lies in the striking similarities shown in their IgG binding specificities. Polyclonal KFs derived from patients with R.A generally possess a similar human IgG subclass specificity to that of HSV-1 Fcy-binding protein in that they preferentially bind to IgG-1, -2 and -4 but not or only weakly to IgG-3 (43, 44) . Like the HSV Fc3~-binding proteins, most polyclonal RFs bind to the CH3 and CH2 interface region of IgG (43, (45) (46) (47) . Studies using chemical modification of amino acids of IgG revealed that Tyr and His residues on IgG seemed to be critical for the binding with KFs (38, 40, 45, 48) and also for binding to the HSV Fc3,-binding protein (47) .
As an alternative to the idiotype-anti-idiotype model, it is conceivable that the viral herpes Fcy-binding protein gE may present the IgG molecule to the host (patients with RA) in such a way that the interface regions between the IgG CH2 and CH3 domains become immunogenic (40) . KF-positive patients with RA have been demonstrated to show an association with the class II HLA antigen DR4 (49, 50) . It is possible that HLA DK4 could somehow influence the immune response against Fc3,-binding proteins such as gE or to autologous anti-Fc3,-binding protein antibodies and that RFs in RA might in turn, therefore, be related somehow to immune responses of genetically predisposed individuals to herpesviruses or to other viral agents possessing IgG Fc'ybinding proteins. Presently, there is no evidence that HLA DR4 functions as a restriction element for HSV-1 immune responsiveness.
Production of KF cannot be ascribed to idiotype-anti-idiotypic responses alone since there is now a large body of experimental and clinical evidence which indicates that immunization with globular proteins, certain carbohydrates, or bacterial antigens may also result in KF induction. The information provided here concerning the reaction between polyclonal or monoclonal IgM human P, Fs and the Fv portions of mAb II-481 can be compared with the precise three-dimensional definition of an idiotope-anti-idiotope complex determined from the crystal structure of a complex between the monoclonal antil~rsozyme Fab D1.3 and the antiidiotopic Fab E225 at 2.5 A resolution (51) . In this latter instance, the private idiotope consisted of 13 amino acid residues mainly from the CDKs of D1.3.7 of the 13 residues made contacts with the original antigen which indicated a significant overlap between idiotype and antigen-combining site. In the case of mAb II-481 studied here, we do not yet have final definition of actual gE antigen binding residues within the mAb II-481 VH or VL CDKs. When this information becomes available with a crystal structure for the gE-mAb II-481 complex, a more selective or precise estimate of idiotope and antigen combining site may become available.
